Atlas Venture

Atlas Venture Atlas Venture has been running for over 30 years and is one of the world's leading biotech-only VCs. The firm operates a two-fund model: Fund XIV ($450M, closed December 2024) for seed and Series A, and Opportunity Fund III ($400M, closed September 2025) for growth-stage follow-on. The company-building track record is substantial. 78 startups launched through the incubator, with 42 IPOs and 37 M&A exits. More than 25 medicines created by portfolio companies have reached patients.